This inventor holds 5 USPTO granted patents. Top assignee: Ludwig Institute for Cancer Research Limited. Active years: 1999-2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999-2002
Title: Jean-Charles Cerrottini: Innovator in Cancer Research
Introduction
Jean-Charles Cerrottini is a prominent inventor based in Epalinges, Switzerland. He has made significant contributions to the field of cancer research, particularly in the development of immunogenic compositions related to tumor rejection antigens. With a total of 5 patents to his name, Cerrottini's work is pivotal in advancing therapeutic strategies against cancer.
Latest Patents
Cerrottini's latest patents include innovative immunogenic compositions of the tumor rejection antigen precursor MAGE-10. These patents encompass isolated cDNA molecules that encode the tumor rejection antigen precursor MAGE-10, the protein itself, and antibodies specific to it. The applications of these inventions are crucial for developing effective cancer treatments.
Career Highlights
Cerrottini is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to push the boundaries of cancer research. His work has been instrumental in understanding the mechanisms of tumor rejection and the potential for immunotherapy.
Collaborations
Some of his notable coworkers include Donata Rimoldi and Victor Jongeneel, who have collaborated with him on various research projects aimed at enhancing cancer treatment methodologies.
Conclusion
Jean-Charles Cerrottini's contributions to cancer research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to inspire advancements in therapeutic approaches to combat cancer effectively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile